Concurrently, integrating resistin into multimodal biomarker panels may enhance risk prediction models and provide a more comprehensive assessment of patient prognosis, ultimately paving the way for more personalized management strategies in cardiovascular diseases. Here, RETN is linked to cardiovascular disorder.